[go: up one dir, main page]

MX2019002265A - Uso de pridopidina para el tratamiento de la disminucion funcional. - Google Patents

Uso de pridopidina para el tratamiento de la disminucion funcional.

Info

Publication number
MX2019002265A
MX2019002265A MX2019002265A MX2019002265A MX2019002265A MX 2019002265 A MX2019002265 A MX 2019002265A MX 2019002265 A MX2019002265 A MX 2019002265A MX 2019002265 A MX2019002265 A MX 2019002265A MX 2019002265 A MX2019002265 A MX 2019002265A
Authority
MX
Mexico
Prior art keywords
functional capacity
pridopidine
patient
functional decline
treating functional
Prior art date
Application number
MX2019002265A
Other languages
English (en)
Other versions
MX390627B (es
Inventor
Hayden Michael
Papapetropoulos Spyridon
Matti Savola Juha-
Eyal Eli
Borowsky Beth
D Grachev Igor
Original Assignee
Prilenia Therapeutics Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Therapeutics Dev Ltd filed Critical Prilenia Therapeutics Dev Ltd
Publication of MX2019002265A publication Critical patent/MX2019002265A/es
Publication of MX390627B publication Critical patent/MX390627B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención proporciona un método para mantener la capacidad funcional, mejorar la capacidad funcional o retardar la disminución de la capacidad funcional en un paciente humano que comprende administrar periódicamente por vía oral al paciente una composición farmacéutica que comprende pridopidina de manera que se administre una dosis de 90-225 mg de pridopidina al paciente por día, para mantener así la capacidad funcional, mejorar la capacidad funcional o retardar la disminución de la capacidad funcional en el paciente humano.
MX2019002265A 2016-08-24 2017-08-24 Uso de pridopidina para el tratamiento de la disminucion funcional. MX390627B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662379175P 2016-08-24 2016-08-24
US201662395263P 2016-09-15 2016-09-15
US201662411511P 2016-10-21 2016-10-21
US201662416685P 2016-11-02 2016-11-02
PCT/US2017/048461 WO2018039477A1 (en) 2016-08-24 2017-08-24 Use of pridopidine for treating functional decline

Publications (2)

Publication Number Publication Date
MX2019002265A true MX2019002265A (es) 2019-10-30
MX390627B MX390627B (es) 2025-03-21

Family

ID=61241181

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019002265A MX390627B (es) 2016-08-24 2017-08-24 Uso de pridopidina para el tratamiento de la disminucion funcional.
MX2022003072A MX2022003072A (es) 2016-08-24 2019-02-25 Uso de pridopidina para el tratamiento de la disminucion funcional.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022003072A MX2022003072A (es) 2016-08-24 2019-02-25 Uso de pridopidina para el tratamiento de la disminucion funcional.

Country Status (17)

Country Link
US (1) US11207310B2 (es)
EP (2) EP3504187B8 (es)
JP (2) JP6912574B2 (es)
CN (2) CN115671103A (es)
AU (2) AU2017315783C1 (es)
BR (1) BR112019003732A2 (es)
CA (2) CA3151507C (es)
CL (2) CL2019000485A1 (es)
DK (1) DK3504187T3 (es)
ES (1) ES3025836T3 (es)
FI (1) FI3504187T3 (es)
HU (1) HUE071008T2 (es)
IL (1) IL311081A (es)
MX (2) MX390627B (es)
PL (1) PL3504187T3 (es)
PT (1) PT3504187T (es)
WO (1) WO2018039477A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013002453A (es) 2010-09-03 2013-08-01 Ivax Int Gmbh Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos.
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
PE20160195A1 (es) 2013-06-21 2016-05-14 Teva Pharmaceuticals Int Gmbh Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
TW201613859A (en) * 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
CA2977264C (en) 2015-02-25 2021-12-07 Teva Pharmaceuticals International Gmbh Use of pridopidine to improve cognitive function and for treating alzheimer's disease
PL3504187T3 (pl) 2016-08-24 2025-06-09 Prilenia Neurotherapeutics Ltd. Stosowanie pridopidyny w leczeniu zaburzeń czynnościowych
DK3503890T3 (da) * 2016-08-24 2025-01-27 Prilenia Neurotherapeutics Ltd Anvendelse af pridopidin til behandling af dystonier
DK3512833T3 (da) 2016-09-15 2020-10-12 Boehringer Ingelheim Int Heteroarylcarboxamidforbindelser som inhibitorer af ripk2
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
EP3678664A1 (en) 2017-09-08 2020-07-15 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
JP2022521457A (ja) * 2019-01-31 2022-04-08 エフ．ホフマン－ラ ロシュ アーゲー ハンチントン病の進行度の評価方法
CN113395964A (zh) 2019-02-04 2021-09-14 普瑞尼亚神经治疗有限公司 用于帕金森氏病和与帕金森症相关的其它疾病的低剂量普利多匹定
CN113950328A (zh) 2019-06-12 2022-01-18 普瑞尼亚神经治疗有限公司 用于治疗亨廷顿病及其症状的包含普利多匹定及其类似物的组合物
BR112022022427A2 (pt) * 2020-05-04 2022-12-13 Prilenia Neurotherapeutics Ltd Tratamento de infecção, doença ou distúrbio viral com o uso de um agonista de s1r seletivo
CN117202906A (zh) * 2021-04-14 2023-12-08 普瑞尼亚神经治疗有限公司 前驱亨廷顿病的治疗
WO2025164698A1 (ja) * 2024-01-31 2025-08-07 株式会社ケイファーマ ハンチントン病治療剤及び治療用組成物

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702716D0 (sv) 1997-07-15 1997-07-15 Ross Nicholas Waters Substituted phenylazacycloalkanes in the treatment of cognitive disorders
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
EP1713486A4 (en) * 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
GT200500063A (es) 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
KR101319235B1 (ko) 2004-10-13 2013-10-16 아이백스 인터내셔널 게엠베하 4-(3-메탄설폰일페닐)-1-ｎ-프로필-피페리딘의 합성 공정
DOP2006000273A (es) 2005-12-08 2007-10-15 Aventis Pharma Inc Uso de un antagonista de cb1 para tratar efectos secundarios y sintomas negativos de la esquizofrenia
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
US20070286902A1 (en) 2006-06-07 2007-12-13 Abrika Pharmaceuticals Dosage forms comprising a short acting sedative-hypnotic or salt thereof
WO2008127188A1 (en) 2007-04-12 2008-10-23 Allbay Ab N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
WO2010008486A2 (en) 2008-06-24 2010-01-21 Parkinsons Institute Pluripotent cell lines and methods of use thereof
US8384755B2 (en) 2009-08-26 2013-02-26 Intouch Technologies, Inc. Portable remote presence robot
KR101762460B1 (ko) 2009-09-24 2017-07-27 캡슈겔 벨지엄 엔브이 내산성 캡슐
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
JP2013532233A (ja) 2010-07-02 2013-08-15 アクティエボラゲット・エスコーエッフ 機械構成要素、および表面硬化方法
MX2013002453A (es) 2010-09-03 2013-08-01 Ivax Int Gmbh Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos.
US8703763B2 (en) 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
EP2710041A4 (en) 2011-05-18 2014-11-05 Parkinson S Inst ASSAY FOR DETERMINING LRRK2 ACTIVITY IN MORBUS PARKINSON
US9006445B2 (en) 2011-09-07 2015-04-14 IVAX International GmbH Polymorphic form of pridopidine hydrochloride
CA2856749A1 (en) 2011-12-08 2013-06-13 IVAX International GmbH The hydrobromide salt of pridopidine
US9744155B2 (en) * 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
US20130267552A1 (en) 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy
WO2014052935A2 (en) 2012-09-27 2014-04-03 Teva Pharmaceutical Industries Ltd. Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
HK1214553A1 (zh) 2012-09-27 2016-07-29 Teva Pharmaceutical Industries Ltd. 用於治疗神经退行性疾病的拉喹莫德和普利多匹定
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
PE20160195A1 (es) * 2013-06-21 2016-05-14 Teva Pharmaceuticals Int Gmbh Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
MX377576B (es) 2014-01-22 2025-03-04 Prilenia Neurotherapeutics Ltd Formulaciones de pridopidina de liberación modificada.
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
JP2018505147A (ja) 2014-12-22 2018-02-22 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー プリドピジンのｌ−酒石酸塩
CA2977264C (en) 2015-02-25 2021-12-07 Teva Pharmaceuticals International Gmbh Use of pridopidine to improve cognitive function and for treating alzheimer's disease
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
WO2017015615A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
WO2017048457A1 (en) 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
CA3015512C (en) 2016-02-24 2024-01-16 Teva Pharmaceuticals International Gmbh Treatment of neurodegenerative eye disease using pridopidine
PL3504187T3 (pl) 2016-08-24 2025-06-09 Prilenia Neurotherapeutics Ltd. Stosowanie pridopidyny w leczeniu zaburzeń czynnościowych
DK3503890T3 (da) 2016-08-24 2025-01-27 Prilenia Neurotherapeutics Ltd Anvendelse af pridopidin til behandling af dystonier
CA3036842A1 (en) 2016-09-15 2018-03-22 Prilenia Therapeutics Development Ltd. Use of pridopidine for the treatment of anxiety and depression
MX388845B (es) 2016-09-16 2025-03-20 Prilenia Neurotherapeutics Ltd Uso de pridopidina para tratar el sindrome de rett.
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
PL3570940T3 (pl) 2017-01-20 2024-06-17 Prilenia Neurotherapeutics Ltd. Pridopidyna do zastosowania w leczeniu zespołu łamliwego chromosomu x
EA202090510A1 (ru) 2017-08-14 2020-06-08 Приления Ньюротерапьютикс Лтд. Способ лечения бокового амиотрофического склероза придопидином
MX2020002310A (es) 2017-08-30 2020-09-17 Prilenia Neurotherapeutics Ltd Formas de dosificacion de alta concentracion de pridopidina.

Also Published As

Publication number Publication date
EP3504187B1 (en) 2025-02-19
CA3035092C (en) 2022-05-31
EP3504187B8 (en) 2025-03-26
HUE071008T2 (hu) 2025-07-28
CN109923102A (zh) 2019-06-21
BR112019003732A2 (pt) 2020-02-18
EP4516356A2 (en) 2025-03-05
EP4516356A3 (en) 2025-05-14
MX390627B (es) 2025-03-21
PL3504187T3 (pl) 2025-06-09
CA3151507A1 (en) 2018-03-01
JP6912574B2 (ja) 2021-08-04
CN115671103A (zh) 2023-02-03
IL311081A (en) 2024-04-01
NZ751156A (en) 2021-01-29
DK3504187T3 (da) 2025-04-14
JP2021119186A (ja) 2021-08-12
AU2017315783C1 (en) 2020-12-24
MX2022003072A (es) 2022-06-17
CL2019000485A1 (es) 2019-07-12
AU2020223736A1 (en) 2020-09-17
WO2018039477A1 (en) 2018-03-01
AU2020223736B2 (en) 2022-04-07
PT3504187T (pt) 2025-05-09
CN109923102B (zh) 2022-11-15
JP2019524898A (ja) 2019-09-05
US11207310B2 (en) 2021-12-28
EP3504187A4 (en) 2020-05-06
EP3504187A1 (en) 2019-07-03
ES3025836T3 (en) 2025-06-09
US20180055832A1 (en) 2018-03-01
AU2017315783B2 (en) 2020-05-28
CA3035092A1 (en) 2018-03-01
FI3504187T3 (fi) 2025-04-05
CL2019003924A1 (es) 2020-05-29
CA3151507C (en) 2024-05-28
AU2017315783A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
MX2019002265A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX2015017307A (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington.
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
CR20180253A (es) Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana
PE20230735A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
AR095338A1 (es) Método de tratamiento no tóxico para la abstinencia de drogas
PH12020550616A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
CL2015003468A1 (es) Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
BR112015012497A8 (pt) combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
BR112018015483A2 (pt) formulações farmacêuticas sólidas estáveis que contêm 2-(2-nitro-4-trifluorometil-benzoil)-1,3 -ciclo-hexanodiona
PH12020500120A1 (en) Pharmaceutical compositions
AR108792A1 (es) Composiciones que comprenden timolol
MX2018001528A (es) Composicion farmaceutica que comprende sumatriptan para tratamiento de migraña.
EA201990553A1 (ru) Применение придопидина для лечения ухудшения функциональной способности
EA202190247A1 (ru) ПРИМЕНЕНИЕ рГЦ СТИМУЛЯТОРОВ ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ
AR111161A1 (es) Régimen de dosificación para el inhibidor sglt1/2 (licogliflozin)
CU20180036A7 (es) Composiciones terapéuticas para el tratamiento del virus de la inmunodeficiencia humana